Goldman Sachs
PTX

Goldman Sachs’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Goldman Sachs’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-15,008
Closed -$36K – 6003
2018
Q2 		$36K Sell
15,008
-693
-4% -$1.7K ﹤0.01% 5422
2018
Q1 		$38K Buy
15,701
+804
+5% +$2.03K ﹤0.01% 5548
2017
Q4 		$36K Sell
14,897
-764
-5% -$2.11K ﹤0.01% 6009
2017
Q3 		$49K Buy
+15,661
New +$50.3K ﹤0.01% 6258
2017
Q2 		– Sell
-25,411
Closed -$94K – 7198
2017
Q1 		$94K Sell
25,411
-1,702
-6% -$5.34K ﹤0.01% 6089
2016
Q4 		$53K Sell
27,113
-5,444
-17% -$19.7K ﹤0.01% 6376
2016
Q3 		$203K Buy
32,557
+8,821
+37% +$54.4K ﹤0.01% 5828
2016
Q2 		$106K Buy
23,736
+10,896
+85% +$71.1K ﹤0.01% 6103
2016
Q1 		$135K Buy
12,840
+1,279
+11% +$25.4K ﹤0.01% 5906
2015
Q4 		$341K Buy
11,561
+7,929
+218% +$240K ﹤0.01% 5247
2015
Q3 		$115K Sell
3,632
-1,141
-24% -$54.6K ﹤0.01% 6403
2015
Q2 		$283K Buy
4,773
+2,252
+89% +$159K ﹤0.01% 5796
2015
Q1 		$269K Sell
2,521
-1,827
-42% -$174K ﹤0.01% 5747
2014
Q4 		$408K Sell
4,348
-12,108
-74% -$1.15M ﹤0.01% 5482
2014
Q3 		$1.26M Sell
16,456
-19,645
-54% -$1.55M ﹤0.01% 4378
2014
Q2 		$3.24M Buy
36,101
+30,557
+551% +$1.87M ﹤0.01% 3486
2014
Q1 		$297K Buy
5,544
+746
+16% +$24.6K ﹤0.01% 5752
2013
Q4 		$121K Buy
+4,798
New +$114K ﹤0.01% 6205

Other funds holding PTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's PTX Position: Q3 2018 in Review

Goldman Sachs sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q3 2018, closing a stake of 15,008 shares — an estimated $36K sold.

Goldman Sachs first reported a position in PTX in Q4 2013 and held it in 18 quarters. The position peaked at $3.24M in Q2 2014. 33 funds tracked by Wall St. Rank hold PTX as of Q3 2018.

  • Goldman Sachs reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q3 2018 after selling out during the quarter.
  • Goldman Sachs sold 15,008 Pernix Therapeutics Holdings, Inc. shares in Q3 2018, an estimated $36K.
  • Goldman Sachs first reported a position in Pernix Therapeutics Holdings, Inc. in Q4 2013 and held it in 18 quarters.
  • Goldman Sachs's Pernix Therapeutics Holdings, Inc. position peaked at $3.24M in Q2 2014.
  • 33 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q3 2018.

Based on Goldman Sachs's 13F filing for Q3 2018, filed 14 Nov 2018.